HRT in South Africa: What It Costs, Who It’s For

Hot flushes at 2 am. Brain fog that makes a work presentation feel impossible. A libido that has quietly left the building. Menopause is not a single bad week — for many South African women it is years of disruption, and hormone replacement therapy (HRT) is still the most effective treatment available. Yet a 2002 American study, widely misreported, has kept millions of women worldwide away from a conversation their GP could have in 15 minutes. It is time to clear the air.

The 2002 scare that still shapes what SA women believe

In 2002 the Women’s Health Initiative (WHI) published findings suggesting HRT raised the risk of breast cancer, heart disease, and stroke. The headlines were global and they were alarming. South African media picked them up, and many women — and some clinicians — quietly shelved the topic.

Here is what those headlines missed. The WHI studied a specific product: oral conjugated equine oestrogen combined with medroxyprogesterone acetate, given to women with an average age of 63 — most of them more than a decade past menopause. The findings do not straightforwardly apply to women in their late 40s or early 50s who start HRT around the time of menopause, nor to the newer transdermal (patch or gel) and body-identical hormone formulations used most often today.

The South African Menopause Society (SAMS) has consistently noted that the WHI results were over-generalised and that the absolute risk increase for breast cancer in the combined HRT arm was roughly 8 extra cases per 10,000 women per year — a real risk worth knowing, but smaller than many everyday comparisons. Drinking more than one alcoholic drink a day, for instance, carries a similar or greater increase in breast cancer risk. No local SA data on HRT-specific breast cancer incidence exists, but SAMS guidance aligns with this reframing.

Who is a good candidate for HRT?

HRT works by replacing oestrogen — and, where you have a uterus, progesterone — that the ovaries stop producing at menopause. The South African Menopause Society says the best candidates are:

• Women under 60, or within 10 years of menopause onset, with moderate to severe symptoms (the “timing hypothesis” or “window of opportunity”)
• Women with premature ovarian insufficiency (POI), where the ovaries stop functioning before age 40 — in these cases HRT is strongly recommended for bone and cardiovascular protection until at least age 51
• Women whose quality of life is significantly affected by vasomotor symptoms (hot flushes, night sweats), mood disruption, vaginal dryness, or sleep problems

HRT is generally not recommended for women with a personal history of certain oestrogen-sensitive cancers, unexplained vaginal bleeding, active liver disease, or a history of blood clots — but these are conversations to have with your doctor, not reasons to self-exclude before the consultation.

In the SA context it is also worth noting that hypertension affects roughly 1 in 3 South African adults according to the South African Medical Research Council (SAMRC), and diabetes prevalence is rising. Both conditions require clinical assessment before starting HRT, not automatic exclusion from it.

What the evidence actually shows today

The current consensus from SAMS and the international Menopause Society is that for healthy women under 60 starting HRT close to menopause, the benefits outweigh the risks for most symptom-related indications. Specifically:

• Vasomotor symptoms: HRT reduces hot flush frequency by roughly 75% compared with placebo in clinical trials.
• Bone protection: HRT maintains bone mineral density and reduces fracture risk; women lose up to 20% of bone density in the five years after menopause.
• Cardiovascular benefit (early use): Starting HRT within 10 years of menopause is associated with a 30–50% lower risk of coronary heart disease compared with non-use — a benefit that disappears or reverses when started late. No dedicated SA cardiovascular HRT trial exists; these figures come from reanalysis of WHI and the KEEPS trial.
• Blood clot risk: Oral oestrogen raises the risk of deep-vein thrombosis; transdermal oestrogen at standard doses does not carry the same signal, making it the preferred route for women with modifiable risk factors.

What HRT actually costs in South Africa

This is where many women hit a wall. Cost varies significantly between the public and private sectors.

Private sector: A first consultation with a gynaecologist in Johannesburg or Cape Town typically costs R900–R1,800 depending on the practice. A GP consultation is R600–R1,100. Monthly HRT products range widely:

• Oral oestrogen/progestogen combination tablets: roughly R180–R450 per month
• Oestrogen patches (e.g. Estradot, Vivelle): R350–R650 per month
• Oestrogen gel (e.g. Oestrogel): R320–R600 per month
• Micronised progesterone capsules (Utrogestan): R250–R450 per month, where prescribed separately

Public sector: Menopause is not classified as a Prescribed Minimum Benefit (PMB) condition, which means medical aids are not legally required to cover HRT or menopause-related consultations in full. In practice, many open medical aid plans cover GP consultations from day-to-day benefits, and some cover generic oral HRT products, but cover varies by plan. Check your benefit schedule directly — do not assume.

At a public clinic or community health centre, oral conjugated oestrogen is available on the Essential Medicines List and is dispensed free of charge to qualifying patients. However, access is inconsistent; stock-outs are a real problem, and transdermal formulations are rarely stocked in the public sector. Women in rural provinces often face an additional transport barrier — a return trip to a district hospital can cost R80–R200 in taxi fare and a full day of work.

Practical workaround: If cost is a barrier, ask your GP to prescribe a generic oral formulation from the Essential Medicines List and ask whether your nearest CHC can dispense it. For women in urban areas, some private pharmacies (Clicks, Dis-Chem) carry generic HRT products that are meaningfully cheaper than originator brands — ask the pharmacist to compare.

How to start the conversation with your doctor

Many women arrive at a GP appointment apologetically, half-expecting to be told they must simply “get through it.” You do not have to approach it that way.

Go in with your symptom picture: how many hot flushes per day, how severely sleep is affected, whether vaginal dryness is affecting your relationship or urinary health. Bring your blood pressure reading if you have it. Ask specifically: “Am I a candidate for HRT, and if so, which route of delivery would you recommend for me?”

If your GP is not confident in menopause management, ask for a referral to a gynaecologist or a menopause specialist. SAMS maintains a directory of member clinicians at www.menopause.co.za.

When to see a doctor

Book a consultation if you are experiencing:

– Hot flushes or night sweats that disrupt sleep or daily function

– Irregular or stopped periods before age 45

– Vaginal dryness, pain during sex, or recurrent urinary infections

– Mood changes or brain fog that feel new and persistent

– Any bleeding after menopause — this always needs investigation, regardless of HRT status

The bottom line

Key takeaways

– The 2002 WHI study applied to older women on a specific oral HRT formulation — its absolute risk numbers are smaller than many headlines suggested and do not apply wholesale to younger, newly menopausal women.

– HRT reduces hot flushes by roughly 75%, protects bone density, and — when started early — is associated with lower cardiovascular risk.

– Transdermal oestrogen carries a lower blood clot risk than oral oestrogen and is the preferred route for many women.

– Menopause is not a PMB condition; check your medical aid benefit schedule before assuming coverage. Generic oral HRT is available free in the public sector but stock reliability varies.

– Ask your GP directly whether HRT is appropriate for you — or ask for a referral to a SAMS-listed specialist if needed.